<DOC>
	<DOCNO>NCT01126879</DOCNO>
	<brief_summary>RATIONALE : Genistein may stop growth tumor cell block enzymes need cell growth . PURPOSE : This randomized phase II trial study well genistein work treat patient prostate cancer .</brief_summary>
	<brief_title>Genistein Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine whether genistein treatment decrease number circulate prostate cell ( CPCs ) peripheral blood measure qRT-PCR PSA perform RNA extract peripheral blood mononuclear cell ( PBMNCs ) . SECONDARY OBJECTIVES : I . Determine natural history circulate prostate cell ( CPCs ) cohort subject prior post radical prostatectomy . II . Compare measurement PSA three separate method : CPCs qRT-PCR , serum standard clinical chemistry assay ( i.e. , ELISA ) , plasma serum nano-PSA assay . III . Measure effect genistein gene protein expression prostate tissue qRT-PCR immunohistochemistry , respectively , follow gene respective protein product : HSP27 , MMP-2 , ALK-2 , BASP1 , HCF2 . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive oral genistein daily 3 month begin least 1 month prior radical prostatectomy . ARM II : Patients receive oral placebo daily 3 month begin least 1 month prior radical prostatectomy . All patient undergo radical prostatectomy least 2 week , 3 month follow start therapy . After completion study treatment , patient follow 1 , 6 , 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>Inclusion Participants must pathologic diagnosis prostate cancer within past 6 month , clinical stage T13 disease , PSA &gt; = 10 , Gleason score &gt; = 8 , elect undergo radical prostatectomy ; find detectable circulate prostate cancer cell blood detect qRTPCR PSA eligible proceed onto treatment phase protocol ; pathology slide use diagnosis submit SPORE tissue pathology core review ECOG performance status 01 Hemoglobin &gt; 9.0gm/dl Platelets &gt; = 100 K/uL ANC &gt; 1000/uL AST ( SGOT ) /ALT ( SGPT ) &lt; 3X upper limit normal Creatinine &lt; 2.0 mg/dl Total bilirubin &lt; 2 mg/dl ( Note : Subjects high level bilirubin due familial defect bilirubin metabolism consider individual basis ) Participants must agree take soy supplement Ability understand willingness sign write informed consent document Willingness take study agent least 2 week prior radical prostatectomy Exclusion History venous thrombosis within past year Participants must receive active therapy neoplastic disorder ( include hormone radiation therapy prostate cancer ) Participants may receive investigational agent Known soy intolerance Medical condition , opinion investigator , would jeopardize either patient integrity data obtain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>